Shibata Tsuyoshi, Mitsuoka Hiroshi, Iba Yutaka, Hashizume Kenichi, Hongo Norio, Yasuhara Kiyomitsu, Kuwada Noriaki, Katada Yoshiaki, Hashiguchi Hitoki, Uzuka Takeshi, Murai Yuta, Nakazawa Tomohiro Junji, Kawaharada Nobuyoshi
Department of Cardiovascular Surgery, Sapporo Medical University, 291, Minami 1-jo Nishi 16-chome, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Department of Cardiovascular Surgery, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Interdiscip Cardiovasc Thorac Surg. 2024 Mar 29;38(4). doi: 10.1093/icvts/ivae044.
Our goal was to evaluate early and mid-term outcomes of physician-modified endografting for pararenal and thoraco-abdominal aortic aneurysms from 10 Japanese aortic centres.
From January 2012 to March 2022, a total of 121 consecutive adult patients who underwent physician-modified endografting for pararenal and thoraco-abdominal aortic aneurysms were enrolled. We analysed early and mid-term postoperative outcomes, including postoperative complications and mortality.
The pararenal and thoraco-abdominal aortic aneurysm groups included 62 (51.2%) and 59 (48.8%) patients, respectively. The overall in-hospital mortality rate was 5.8% (n = 7), with mortality rates of 3.2% (n = 2) and 8.5% (n = 5) in pararenal and thoraco-abdominal aortic aneurysm groups, respectively (P = 0.225). Type IIIc endoleaks occurred postoperatively in 18 patients (14.9%), with a significantly higher incidence (P = 0.033) in the thoraco-abdominal aortic aneurysm group (22.0%, n = 13) than in the other group (8.1%, n = 5). Major adverse events occurred in 7 (11.3%) and 14 (23.7%) patients in pararenal and thoraco-abdominal aortic aneurysm groups (P = 0.074), respectively. The mean follow-up period was 24.2 months. At the 3-year mark, both groups differed significantly in freedom from all-cause mortality (83.3% and 54.1%, P = 0.004), target aneurysm-related mortality (96.8% and 82.7%, P = 0.013) and any reintervention (89.3% and 65.6%, P = 0.002). Univariate and multivariate regression analyses demonstrated that ruptures, thoraco-abdominal aortic aneurysms and postoperative type IIIc endoleaks were associated with an increased risk of all-cause mortality.
The mid-term outcomes of physician-modified endografting for pararenal and thoraco-abdominal aortic aneurysms were clinically acceptable and comparable with those in other recently published studies. Notably, pararenal and thoraco-abdominal aortic aneurysms represent distinct pathological entities with different postoperative outcomes.
我们的目标是评估来自日本10个主动脉中心的经医生改良的肾旁和胸腹主动脉瘤腔内修复术的早期和中期结果。
从2012年1月至2022年3月,共有121例连续接受经医生改良的肾旁和胸腹主动脉瘤腔内修复术的成年患者纳入研究。我们分析了术后早期和中期结果,包括术后并发症和死亡率。
肾旁主动脉瘤组和胸腹主动脉瘤组分别有62例(51.2%)和59例(48.8%)患者。总体住院死亡率为5.8%(n = 7),肾旁主动脉瘤组和胸腹主动脉瘤组的死亡率分别为3.2%(n = 2)和8.5%(n = 5)(P = 0.225)。18例患者(14.9%)术后发生IIIc型内漏,胸腹主动脉瘤组的发生率(22.0%,n = 13)显著高于另一组(8.1%,n = 5)(P = 0.033)。肾旁主动脉瘤组和胸腹主动脉瘤组分别有7例(11.3%)和14例(23.7%)患者发生主要不良事件(P = 0.074)。平均随访期为24.2个月。在3年时,两组在全因死亡率(83.3%和54.1%,P = 0.004)、目标动脉瘤相关死亡率(96.8%和82.7%,P = 0.013)和任何再次干预(89.3%和65.6%,P = 0.002)方面存在显著差异。单因素和多因素回归分析表明,破裂、胸腹主动脉瘤和术后IIIc型内漏与全因死亡风险增加相关。
经医生改良的肾旁和胸腹主动脉瘤腔内修复术的中期结果在临床上是可接受的,并且与其他最近发表的研究结果相当。值得注意的是,肾旁和胸腹主动脉瘤代表了具有不同术后结果的不同病理实体。